Newswise Focus Channel: Cancer Center Featured Story 2

Roswell Park-Designed Treatment Regimen Doubles Progression-Free Survival in Metastatic Kidney Cancer

Roswell Park Comprehensive Cancer Center — Sun, 15 Sep 2024 11:05:00 EST

During the European Society for Medical Oncology (ESMO) Congress, Saby George, MD, FACP, of Roswell Park Comprehensive Cancer Center presented findings on a novel two-agent treatment that more than doubled progression-free survival compared with single-agent treatment.

ESMO: Combination Therapy Reduced Agitated Delirium in Patients with Advanced Cancers

University of Texas MD Anderson Cancer Center — Sat, 14 Sep 2024 09:45:00 EST

Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life condition for patients with advanced cancers, compared with haloperidol alone, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center.

Antibody-Drug Conjugate Found Effective Against Brain Metastases in Patients with HER2-Positive Breast Cancer

Dana-Farber Cancer Institute — Fri, 13 Sep 2024 11:05:28 EST

A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2-positive breast cancer. Research led by Dana-Farber Cancer Institute.

Repeat Immune Checkpoint Inhibitor Therapy Not Recommended for Advanced Kidney Cancer

Dana-Farber Cancer Institute — Fri, 13 Sep 2024 10:05:02 EST

In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab to treatment with tivozanib for patients with advanced clear cell renal cell carcinoma.

ESMO: Novel ADC AZD8205 Demonstrates Manageable Safety Profile and Preliminary Efficacy in First-in-Human Trial

University of Texas MD Anderson Cancer Center — Fri, 13 Sep 2024 09:05:13 EST

The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced or metastatic solid tumors, according to interim data shared today at the 2024 European Society for Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.

Residents in San Joaquin Valley Breathe Chemical Pesticides, According to New Study

UC Davis Health — Thu, 12 Sep 2024 17:05:23 EST

A UC Davis Health study found 22% of adults and 10% of children who participated in an air-quality study in California's San Joaquin Valley were breathing detectable levels of pesticides.

NCCN Commits to Sharing Award-Winning Resources for People with Cancer in Spanish and Other Languages

National Comprehensive Cancer Network(r) (NCCN(r)) — Thu, 12 Sep 2024 08:55:29 EST

The National Comprehensive Cancer Network (NCCN) and the NCCN Foundation announce plans to make every book in the library of NCCN Guidelines for Patients available in Spanish; with select editions available in additional languages as well.

New, Rare Type of Small Cell Lung Cancer Identified by MSK Research Team

Memorial Sloan Kettering Cancer Center — Wed, 11 Sep 2024 15:05:40 EST

A team of doctors and researchers at MSK have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never smoked. Learn how one 19-year-old patient sparked a detective story.

Comprehensive cancer research from Dana-Farber to lead ESMO Congress 2024

Dana-Farber Cancer Institute — Wed, 11 Sep 2024 08:35:00 EST

Novel treatments, including targeted therapies and antibody drug conjugates, as well as research into improving quality of life for patients with breast cancer, headline studies led by Dana-Farber Cancer Institute and presented at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain.

NCCN Policy Summit Explores how to Build an Inclusive Cancer Center Workplace Culture that Better Serves Everybody

National Comprehensive Cancer Network(r) (NCCN(r)) — Tue, 10 Sep 2024 14:00:57 EST

Speakers at an NCCN Oncology Policy Summit discuss the importance of diversity, equity, and inclusion (DEI) as integral to the oncology workforce to improve cancer outcomes, and what to do about backlash.

MD Anderson Research Highlights Special Edition: ESMO 2024

University of Texas MD Anderson Cancer Center — Tue, 10 Sep 2024 10:00:01 EST

The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.

Mark Awad Named Chief of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center — Tue, 10 Sep 2024 09:00:00 EST

Mark Awad, MD, PhD, has been appointed Chief of the Thoracic Oncology Service within the Solid Tumor Oncology Division, Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK).

MD Anderson Research Highlights Special Edition: 2024 World Conference on Lung Cancer

University of Texas MD Anderson Cancer Center — Mon, 09 Sep 2024 14:05:55 EST

The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. This special edition features compelling data on lung cancer advances presented by MD Anderson researchers at the 2024 World Conference on Lung Cancer.

Cancer Research Institute (CRI) Appoints Alicia Zhou, PhD, as Chief Executive Officer to Advance Next Generation of Cancer Immunotherapy Science and Innovation

Cancer Research Institute — Mon, 09 Sep 2024 12:10:29 EST

The Cancer Research Institute (CRI) has appointed Alicia Zhou, PhD, as its new Chief Executive Officer (CEO).

How the Scars of Demolished Brain Tumors Seed Relapse

Ludwig Cancer Research — Mon, 09 Sep 2024 12:05:48 EST

A Ludwig Cancer Research study has discovered that recurrent tumors of the aggressive brain cancer glioblastoma multiforme (GBM) grow out of the fibrous scars of malignant predecessors destroyed by interventions such as radiotherapy, surgery and immunotherapy.

TGF-Beta and RAS Signaling Are Both Required for Lung Cancer Metastasis, Study Finds

Memorial Sloan Kettering Cancer Center — Fri, 06 Sep 2024 13:05:47 EST

MSK researchers have identified two signaling pathways that work together to spur the spread of lung cancer. Taking away one of those signals could help slow or stop metastasis, findings in animal models suggest.

Global Experts Converge at CICON24 to Unveil Groundbreaking Advances in Cancer Immunotherapy, September 8-11, 2024 at National Harbor, MD

Cancer Research Institute — Fri, 06 Sep 2024 12:20:45 EST

CRI is co-hosting CICON24 to illuminate pioneering advances in cancer immunotherapy research starting September 8 in National Harbor, MD.

Ovarian Cancer: What Every Woman Should Know

Rutgers Cancer Institute — Thu, 05 Sep 2024 12:05:53 EST

Ruth D. Stephenson, DO, FACOG, gynecologic oncologist at RWJBarnabas Health and Rutgers Cancer Institute, New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, addresses five frequently asked questions about ovarian cancer.

Tip Sheet: 20 years since EGFR discovery, aging and immune function, and immunotherapy leader Dr. Lawrence Fong joins Fred Hutch

Fred Hutchinson Cancer Center — Thu, 05 Sep 2024 09:05:36 EST

Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.

Moffitt Researchers Reveal Key LAG3 Mechanisms That Could Transform Cancer Immunotherapy

Moffitt Cancer Center — Wed, 04 Sep 2024 11:00:50 EST

Immune checkpoint inhibitors are a type of cancer treatment that helps the immune system attack cancer cells more effectively. One of the key proteins involved in this process is Lymphocyte Activation Gene-3 (LAG3), which suppresses the antitumor immune response.